# Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

> **NCT00667810** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 901 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** bapineuzumab
- **DRUG:** bapineuzumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00667810
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2012-10
- **Final completion:** 2013-08
- **Target enrollment:** 901 (ACTUAL)
- **Why stopped:** The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.
- **Last updated:** 2016-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667810, "Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00667810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*